At least 64 biopharma companies have announced workforce reductions so far in 2023, resulting in 6,000 jobs lost in the industry. It is a clear indication of a continuing trend begun last year in which executives needed to rein in spending to keep innovative programs afloat. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Hipra Human Health SLU’s recombinant COVID-19 vaccine, Bimervax, as a booster in people ages 16 and older who have been vaccinated with an mRNA COVID-19 vaccine. Read More
Centessa Pharmaceuticals plc’s launch of a phase I/IIa trial with LB-101, a PD-L1xCD47 candidate that emerged from the Lockbody platform, highlighted the firm’s efforts against solid tumors. But the diversified company has more in the works, including a registrational study with subcutaneous (subcu) Serpinpc, designed to treat hemophilia (hemo) B. Centessa has a program in narcolepsy, too. Read More
Smart Immune SAS has received €17.5 million (US$19 million) in grant and equity funding from an EU innovation program to advance development of its “thymus in a dish” T-cell therapy. Read More
It all goes to show how a good idea can’t be kept down. Madam Curie started radiopharmaceuticals in the late 1800s and now it’s a multibillion-dollar industry. On Monday, April 3, BioWorld launches an eight-part series on the new era of radiopharmaceuticals, a key to cancer treatments that have fewer side effects and cause far less damage to tissue than before. The big idea is taking the hallmarks of two cancer therapies – radiology and chemotherapy – and merging them. That’s what makes this evolving technology a disrupter. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astellas, Immunoprecise, Immusoft, Psilera, Trevena, Xyphos. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akebia, Akero, Algo, Athos, Comanche, Decibel, Immvira, Merck & Co., Pacira, Pathovax, Renovion, Vistagen. Read More
